Background: Chronic infection with hepatitis B virus causes a spectrum of diseases ranging from asymptomatic infective state to cirrhosis and hepatocellular carcinoma. The detection and quantification of HBV DNA plays an important role in diagnosing HBV infection as well as monitoring therapeutic responses. Methods: The aim of this study was to detect and quantited HBV DNA by real time PCR and to find out correlation HBeAg with HBV DNA in chronic carriers: The present study carried out among 61 previously diagnosed chronic hepatitis B patients. Results: The mean age of study population was 29.20 years. Among the 61 cases, 13(21.3%) were HBeAg positive and 48(78.7%) were HBeAg negative. By real time PCR, DNA detected in 45(73.8%) patients and 16(26.2%) patients were undetected. Association of HBeAg and HBV DNA was observed in 13 HBeAg positive cases, where 12(92.3%) had detectable DNA and in 48 HBeAg negative patients, 33(68.8%) had detectable DNA while 15(31.2%) were undetected. The present study observed a higher viral load (10 5 copies/ml) among HBeAg positive patients (84.6%) than HBeAg negative patients (12.5%). Conclusion: The present study observed that, there was positive correlation among HBeAg and HBV DNA in chronic HBV carriers. However, there was some discordance observed among HBeAg and HBV DNA. Therefore, in addition to HBeAg, HBV DNA should be assessed for appropriate evaluation of CHB carriers.
INTRODUCTION
HBV (Hepattis B Virus) infection is highly prevalent worldwide as a cause of morbidity and mortality through its consequences such as acute hepatitis, chronic active or persistent hepatitis, cirrhosis of liver and primary hepatocelluler carcinoma. Globally over 2 billion people have been infected with HBV and 350 to 400 million are chronic carriers. Approximately 15% -40% of them develop complication, namely cirrhosis of liver or hepatocelluler carcinoma and among them, around 660,000 die annually due to consequences of this infection [1] [2] . Of the estimated 50 million new cases of HBV infection diagnosed annually, 5-10% of adults and up to 90% of infants will become chronically infected, 75% of these in Asia, where hepatitis B is the leading cause of chronic hepatitis, cirrhosis and hepatocellular carcinoma 3 .
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There are well-known geographical differences in the prevalence of HBV infection. The dynamics of chronic HBV infection differ considerably between the East (Prevalence >10%) and the West (Prevalence <1%) 4 . In most low prevalent areas (Developed countries of America, Western Europe and Australia), HBV infection is acquired mainly during adolescence and mid adulthood and horizontal transmission is predominate, whereas early childhood and perinatal transmission is the main route in high prevalence (Developing countries of Asia, Africa and the Pacific Islands). 11 . Most of the clinicians still depend on patients HBeAg / antiHBe status and liver enzymes especially ALT for defining the degree of infectivity 12 . The advent of molecular biology-based techniques has added a new dimension to the diagnosis and treatment of patients with chronic HBV infection 13 . Viral load tests that quantify HBV in peripheral blood i.e serum or plasma are currently the most useful and most widely used. High sensitivity molecular assays are clearly important for the diagnosis of HBeAg negative CHB and occult HBV, where viral loads can be quite low. Serum HBV DNA is the most important and reliable marker for monitoring hepatitis B viral replication and HBV DNA detection and HBV DNA level measurement is essential for the diagnosis, decision to treat and subsequent monitoring of patients 13 . Traditionally seroconversion of HBeAg to anti-HBe coincides with the decrease or normalization of serum ALT concentration and a very low level of HBV replication 14 . But some studies have concluded that presence or absence of HBeAg may not necessarily reflect the serum HBV DNA concentration, particularly in persistent infection and thus absence of HBeAg poorly correlates with complete loss of HBV DNA from the serum. In some studies found that presence of HBV DNA in 83-100% of HBeAg positive carriers and in 26-64% of HBeAg negative cases 12 . So this study has been designed to detect HBeAg by Enzymelink immunosorbent assay (ELISA) and correlate with HBV DNA by Polymerase Chain Reaction (PCR) method.
MATERIALS AND METHODS
The study was carried out in the Department of Microbiology, Chittagong Medical College and Chevron clinical laboratory, Chittagong, during the period of Jan'12 to Dec'12. Patients were selected from outdoor patients, department of Medicine, Chittagong Medical College Hospital, Chittagong. Inclusion criteria: Patients who were HBsAg positive for at least 6 months. Samples were collected after taking informed consent from patients or his / her legal guardian. Under all aseptic precaution, about 5 ml of venous blood were collected from the patients in a sterile vacutainer. After separation of serum (Blood centrifuged at 3000 rpm by using micropipette in eppendrope tube) ELISA were done for HBsAg and HBeAg detection and rest of serum were preserved at -70 o C immediately till further use for nucleic acid detection. 
RESULTS

Among
DISCUSSION
Hepatitis B Virus (HBV) remains an important cause of acute and chronic hepatitis, cirrhosis and hepatocellular carcinoma in endemic areas. Although the incidence of new infection has decreased after the introduction of vaccination programmes, HBV infection is still a significant problem in the world. It is estimated that over 350 million persons have chronic hepatitis and more than one million individuals die of HBV-related chronic liver disease annually. More than 70% of patients with complications of cirrhosis and hepatocellular carcinoma are negative for hepatitis B e antigen (HBeAg). As such, although the disease may become quiescent in some patients after HBeAg seroconversion, the disease can progress, and most disease related deaths occur in these patients. In the present study, 61 serologically diagnosed CHB patients were enrolled for the detection of HBeAg and quantitation of HBV DNA by Real time PCR method. The study found a male predominance (Male:female ratio of 4.08:1) among the study population. A study by Raihan (2010) and Majid (2011) also observed male predominance in Bangladesh with a male to female ratio of 4.8: 1 and 3.76: 1 respectively. The mean age of the study population in the present study was 29.20 ± 9.76 years. Higher prevalence rate (52.4%) was observed in 21-30 years. In Bangladesh similar findings was also observed by Raihan (2010) and Majid (2011) in Dhaka, where mean age ranges were 30.51 ± 9.61 and 32.05 ± 12.99 years respectively. Similarly mean age ranges were also observed 33.1 ± 8.4 in India and 31.47 ± 7.81 in Egypt 15 . All these observations support that younger populations are more affected by CHB infection. It may be due to their greater exposures and interaction in society as compared to children and aged persons. In the present study, 78.7% cases were found to be negative for HBeAg. Similar HBeAg negative cases were found by Raihan (2010) and Majid (2011) in Dhaka which were 63% and 88.57% respectively. Due to mutation in core promoter and precore regions, HBeAg negativity occurs in CHB patients, which decrease or prevent the synthesis of HBeAg but do not impair viral replication. Among 13 HBeAg positive cases, 12 were found to be positive for HBV DNA by Real time PCR while 1 case had undetectable HBV DNA. Similar finding was reported by Majid (2011) in Bangladesh and Lahiri et al. (2007) in India, they found 1 case and 3 cases which were HBeAg positive but were negative for HBV DNA by PCR respectively. It has been reported that HBeAg may be synthesized and secreted in the absence of an intact virus assembly and this phenomenon may be related to the integration of viral DNA into the host genome with loss of the replication stage. Alternatively, the discordance may have been due to HBV DNA clearance prior to HBeAg clearance, as reported in a follow-up study 16 . 18 .
CONCLUSION
It may be concluded that, detection of HBeAg and HBV DNA among chronic HBV carriers has positive correlation with some discordance observed among HBeAg and HBV DNA. For appropriate evaluation of CHB carriers, HBV DNA may require independent determination in chronic carriers who show discordance between HBeAg and HBV DNA. However, this study has limited by lack of genotyping for HBV and determining the frequency of precore/core promoter mutation among HBeAg negative patients.
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